This research matters to the many people who take blood-thinning medications like aspirin, clopidogrel, or warfarin and may need a breast biopsy. A biopsy is a procedure where doctors remove a small piece of breast tissue to check for cancer or other conditions. Many patients and doctors worry about whether it's safe to continue these important medications during the procedure, as stopping them could increase the risk of heart attacks or strokes. This review aimed to provide clearer guidance by looking at what actually happens when patients keep taking their blood thinners through a biopsy.
The researchers conducted a systematic review and meta-analysis, which means they carefully searched for and combined the results of all relevant studies on this topic. They found eight studies that included a total of 11,524 patients. Of these, 1,154 patients were continuing their antithrombotic therapy (blood thinners) during an image-guided breast biopsy, while 10,370 patients were not on these medications. The researchers then pooled the data from these studies to get a clearer overall picture of the bleeding risks.
The main finding was that continuing blood thinners does increase the chance of some bleeding. Specifically, about 17.9% of patients on blood thinners (203 out of 1,154) experienced a bleeding event, compared to 10.7% of patients not on these drugs (1,110 out of 10,370). In simpler terms, for every 100 patients on blood thinners, about 18 had some bleeding, versus about 11 out of 100 patients not on the drugs. The most important finding, however, was about serious bleeding. The review found that 'clinically relevant' bleeding—meaning bleeding that required medical attention or affected the patient's care—was extremely uncommon. In the one study that reported this specifically, it happened to only about 0.23% of patients, or roughly 2 to 3 people out of every 1,000.
Regarding safety, the primary concern was bleeding. The data suggests that while minor bleeding (like bruising or small amounts of blood at the biopsy site) is more common, it is usually not dangerous. The serious bleeding events that did occur were very rare. The studies did not report whether patients had to stop their medications due to side effects or how tolerable the procedures were with continued therapy.
There are several important reasons not to overreact to this single review. First, the evidence comes from observational studies, which can show a link but cannot prove that continuing blood thinners directly caused the increased bleeding. Other factors might be involved. Second, the eight included studies used different types of blood thinners, different biopsy techniques, and, crucially, different definitions for what counted as a 'clinically relevant' bleeding event. This variability makes it hard to draw one-size-fits-all conclusions. The authors themselves note the evidence is 'burdened by unstandardized reporting and data fragmentation.'
For patients right now, this review realistically supports the current practice of performing image-guided breast biopsies without routinely stopping ongoing antithrombotic therapy. The increased risk appears to be mostly for minor, manageable bleeding, while the risk of serious complications remains very low. This information can help patients and their doctors have a more informed conversation about the risks and benefits. The decision should always be personalized, considering the specific blood thinner, the reason it's being taken, and the individual patient's health. Patients should never stop or change their medication regimen based on this review alone; any decision must be made in consultation with their healthcare team.